Co-Diagnostics, Inc. Invited to Ring Nasdaq Opening Bell Following Several Milestone Events
January 09 2020 - 5:30AM
Business Wire
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of diagnostic tests, announced today that it has been
recognized as a company that represents the Nasdaq Biotech Index in
leading the nation in solving America’s Healthcare challenges
following a year of several Company milestones, and invited to ring
the Nasdaq Stock Market opening bell on January 13 in San
Francisco, California.
“2019 was a momentous year for Co-Diagnostics,” commented
Company CEO Dwight Egan. “Among other things, this past year saw
the completion and CE marking of our first multiplex diagnostic,
for Zika/dengue/chikungunya; the launch of several multiplex tests
for the mosquito abatement market and recording our first domestic
revenue from that vertical; an expansion of our license agreement
with LGC, Biosearch for the CoPrimer™ technology; and of course the
inauguration of our joint venture manufacturing facility in India,
which was later followed by receiving IVD approval for 5 diagnostic
assays from the India equivalent of the FDA. This latter milestone
represents one of the most significant achievements of the Company
to date in terms of growth, credibility of our technology platform,
and anticipated financial impact.
“We extend our gratitude to all shareholders, investors,
customers, and partners for their support, and hope you will join
us as we build on these milestones to make 2020 the best year yet
for CODX.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release may include statements regarding the (i) use of
funding proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in certain verticals or markets, (iv)
capital resources and runway needed to advance the Company’s
products and markets, (v) increased sales in the near-term, (vi)
flexibility in managing the Company’s balance sheet, (vii)
anticipation of business expansion, and (viii) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. The Company does not
undertake any obligation to update any forward-looking statement
relating to matters discussed in this press release, except as may
be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200109005155/en/
Andrew Benson Head of Investor Relations +1 801-438-1036
investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2024 to May 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From May 2023 to May 2024